PRRT2 and Autoimmunity: Furthermore, PKC-θ inhibitor-treated Tregs were more potent than untreated Tregs in preventing inflammatory colitis in vivo (Zanin-Zhorov et al., 2010), supporting the potential clinical application of PKC-θ inhibitors for Treg-mediated treatment of autoimmunity.